(Reuters) -Halozyme Therapeutics said on Friday it had withdrawn its proposal to acquire Evotec SE for 2 billion euros ($2.09 billion) as the German drug developer was unwilling to engage in discussions.
Shares of Halozyme rose 11% to $51, while U.S.-listed shares of Evotec fell 18% to $4.4 in premarket trading.
Halozyme’s requests to meet and engage with Evotec’s Iris Löw-Friedrich, chairwoman of its supervisory board, were not accepted, the company said.
It had proposed to buy all shares of Evotec earlier this month at 11 euros per share.
($1 = 0.9587 euros)
(Reporting by Sriparna Roy in Bengaluru; Editing by Devika Syamnath)
